Open Access

Integrin αVβ3‑targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts

  • Authors:
    • Bin Chen
    • Wenqi Zhang
    • Bin Ji
    • Qingjie Ma
    • Dandan Li
    • Shi Gao
  • View Affiliations

  • Published online on: January 29, 2018     https://doi.org/10.3892/ol.2018.7901
  • Pages: 4201-4206
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The present study aimed to determine the utility of 99mTc-3PRGD2 single photon emission computed tomography (SPECT)/computed tomography (CT) for the non‑invasive monitoring of the response of integrin αvβ3 expression to anti‑angiogenic treatment with bevacizumab. Bevacizumab or vehicle therapy was performed in athymic nu/nu mice bearing A549 lung tumors (moderately high integrin αvβ3 expression) or PC‑3 prostate tumors (low integrin αvβ3 expression) at a dose of 1 mg twice a week. The average tumor volume was 180±90 mm3 the day prior to baseline SPECT/CT. Longitudinal 99mTc‑3PRGD2 SPECT/CT imaging was performed at baseline (‑1 day) and at days 5 and 15. Tumors were harvested at all imaging time points for histopathological analysis with hematoxylin and eosin (H&E) and immunohistochemistry staining. Results revealed a significant difference in tumor volume between vehicle‑ and bevacizumab‑treated groups at 5 and 15 days following the start of treatment in the A549 lung model (P<0.05). At 5 days after the start of therapy, the percent injected dose per gram of tissue (%ID/g) and tumor‑to‑muscle ratio for bevacizumab‑treated A549 declined persistently (P<0.05). However, for the vehicle‑treated A549 model, the %ID and %ID/g value increased 5 days after the start of treatment (P<0.05). For the PC‑3 model, slow‑growing tumors and low tumor uptake was observed throughout the study. Alterations in tumor vasculature were confirmed by histopathological H&E analysis and immunohistochemistry. In conclusion, longitudinal imaging using 99mTc‑3PRGD2 SPECT/CT may be a useful tool for monitoring the anti‑angiogenic effect of bevacizumab therapy.

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, B., Zhang, W., Ji, B., Ma, Q., Li, D., & Gao, . (2018). Integrin αVβ3‑targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts. Oncology Letters, 15, 4201-4206. https://doi.org/10.3892/ol.2018.7901
MLA
Chen, B., Zhang, W., Ji, B., Ma, Q., Li, D., Gao, ."Integrin αVβ3‑targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts". Oncology Letters 15.4 (2018): 4201-4206.
Chicago
Chen, B., Zhang, W., Ji, B., Ma, Q., Li, D., Gao, ."Integrin αVβ3‑targeted SPECT/CT for the assessment of Bevacizumab therapy in orthotopic lung cancer xenografts". Oncology Letters 15, no. 4 (2018): 4201-4206. https://doi.org/10.3892/ol.2018.7901